The overall sensitivity and specificity of serum TKTL1 levels in distinguishing oral squamous cell carcinoma patients, prostate cancer patients, and healthy controls were 90.6% and 95.9%, respectively. This evidence concerns the gene TKTL1 and prostate carcinoma.